Recurrence risk of oculorespiratory syndrome after influenza vaccination: Randomized controlled trial of previously affected persons

Archives of Internal Medicine

Volumn 164, Issue 20, 2004, Pages 2266-2272

  De Serres, Gaston ^a,b   Skowronski, Danuta M ^c   Guay, Maryse ^a,d   Rochette, Louis ^b   Jacobsen, Karen ^e   Fuller, Theresa ^e   Duval, Bernard ^a,b  

^a INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d Dir de S Pub de la Monteregie   (Canada)

^e Westcoast Clinical Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVIRAL; INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COUGHING; DRUG HYPERSENSITIVITY; DYSPHAGIA; EYE IRRITATION; EYE PAIN; FACE EDEMA; FEMALE; FOLLOW UP; HOARSENESS; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; PRIORITY JOURNAL; RECURRENCE RISK; SORE THROAT; THORAX PAIN; WHEEZING;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CANADA; CROSS-OVER STUDIES; EYE INFECTIONS; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROBABILITY; RECURRENCE; REFERENCE VALUES; RESPIRATORY TRACT INFECTIONS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SYNDROME; VACCINATION;

EID: 7544250479     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.20.2266     Document Type: Article

References (19)

1. Health Canada. Oculo-respiratory syndrome in association with the influenza vaccine: Canada, October-November 2000. Can Commun Dis Rep. 2000;26:201-202.
2. Boulianne N, De Serres G, Duval B, Shadmani R, Rochette L. Clinical manifestations and incidence of oculo-respiratory syndrome following influenza vaccination: Quebec, 2000. Can Commun Dis Rep. 2001;27:85-90.
3. National Advisory Committee on Immunization (NACI). Supplementary statement for the 2001-2002 season: influenza vaccination of persons who experienced oculo-respiratory syndrome following previous influenza vaccination. Can Commun Dis Rep. 2001;27:1-7.
4. Skowronski DM, Strauss B, De Serres G, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis. 2003;36:705-713.
5. De Serres G, Grenier J-L, Toth E, et al. The clinical spectrum of the oculorespiratory syndrome after influenza vaccination. Vaccine. 2003;21:2354-2361.
6. Orr P. Supplementary statement for the 2002-2003 season: update on oculorespiratory syndrome in association with influenza vaccination. Can Commun Dis Rep. 2002;28:1-8.
7. De Serres G, Boulianne N, Duval B, et al. Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine. Vaccine. 2003;21:2346-2353.
8. Khromova A, Pool V, Chen R. Oculo-respiratory syndrome following influenza vaccine - United States 1990-2002: new or previously unrecognized? Paper presented at: 52nd Annual Scientific Epidemic Intelligence Service (EIS) Conference; March 31-April 4, 2003; Atlanta, Ga.
9. Skowronski DM, De Serres G, Scheifele D, et al. Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected. Clin Infect Dis. 2003;37:1059-1066.
10. Skowronski DM, Strauss B, Kendall P, Duval B, De Serres G. Low risk of recurrence for persons previously affected by oculo-respiratory syndrome (ORS): implications for influenza re-vaccination. CMAJ. 2002;167:853-858.
11. Grenier J-L, Toth E, De Serres G, et al. Safety of revaccination of patients affected by the oculo-respiratory syndrome (ORS) following influenza vaccination. Can Commun Dis Rep. 2004;30:9-16.
12. Scheifele DW, Duval B, Russell ML, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis. 2003;36:850-857.
13. Diggle PJ, Liang KY, Zeger SL. The Analysis of Longitudinal Data. New York, NY: Oxford University Press; 1994.
14. La Montagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine: 1978. Rev Infect Dis. 1983;5:723-736.
15. American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001;345:1529-1536.
16. Al-Mazrou A, Scheifele DW, Soong T, Bjornson G. Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. CMAJ. 1991;145:213-218.
17. Spila-Alegiani S, Salmaso S, Rota MC, et al. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Vaccine. 1999;17:1898-1904.
18. Skowronski DM, De Serres G, Hébert J, et al. Skin testing to evaluate oculorespiratory syndrome (ORS) associated with influenza vaccination during the 2000-2001 season. Vaccine. 2002;20:2713-2719.
19. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2003-2004 season. Can Commun Dis Rep. 2003;29:1-20.